This paper examines Neuronetics, Inc., a privately held medical device company whose flagship product — the NeuroStar transcranial magnetic stimulation (TMS) system — became the first FDA-approved TMS device for treating major depression. Using a SWOT framework, the paper identifies the company's first-mover advantage and strong investor backing as key strengths, while acknowledging scientific skepticism as a notable weakness. It highlights the unmet clinical need for non-invasive depression treatment as a central market opportunity and discusses competitive entry as the primary threat. The paper then proposes a three-phase business strategy emphasizing quality-driven growth, market expansion, and eventual global reach to ensure long-term sustainability.
Neuronetics, Inc. is a privately held maker and distributor of medical devices for non-invasive procedures. The company focuses on devices that use MRI-strength magnetic field pulses for the treatment of psychiatric and neurological disorders. Their key accomplishment is the development of transcranial magnetic stimulation (TMS) therapy as a means to modulate neurons in the brain as a treatment for major depression and other related psychological disorders. The following outlines the competitive outlook for the company and presents a comprehensive business strategy for expanding the existing market.
TMS works by altering the magnetic fields in the brain, thereby stimulating brain activity in ways that can help treat a variety of conditions, including major depression. Research is currently underway to determine whether magnetic fields may also be useful in treating other neurological disorders (Fitzgerald, Fountain, & Daskalakis, 2006). The topic of TMS has drawn considerable attention from academic researchers, and numerous studies document the physical effects of the treatment on the brain and neurons. Evidence of TMS effects on brain activity is supported by MRI observation (Fitzgerald, Fountain, & Daskalakis, 2006). TMS technology forms the basis for the product line of TMS stimulators currently being marketed by Neuronetics.
The key strength that Neuronetics, Inc. holds over its competition is that it currently has the only TMS device with FDA approval. The NeuroStar TMS has passed FDA safety and efficacy tests and can now be distributed in the United States. Neuronetics is the first company to gain approval for a device of this kind. Academic support for this type of device is well established, yet the NeuroStar TMS remains the first to clear the FDA approval process.
Being first on the market gives Neuronetics, Inc. and the NeuroStar TMS a decided advantage over any competition that may emerge later. Neuronetics has the ability to set the initial price of the machines and to be the first to develop clinical practices surrounding them. Their key strength lies in building brand equity and becoming identified as the originator of this class of device. Proper marketing means that the Neuronetics name can become associated with cutting-edge technology, making the introduction of future devices easier because customers already recognize the brand.
Neuronetics, Inc. is an expanding company with nearly unlimited growth potential. The NeuroStar TMS is only the first device the company intends to market, and major investors have provided sufficient backing to support continued marketing, research, and development. The confidence of major investors signals that the venture is considered a sound risk, which itself represents a key strength.
One key weakness is that the theory behind the device has been accused of being impossible to validate according to modern clinical standards (Zwillich, 2007). Even though these criticisms are largely unfounded and the scientific support for the device is substantial, such voices will continue to influence public opinion. This lack of broad consensus represents a weakness in the ability to market the NeuroStar TMS successfully.
It is expected that this weakness can be overcome over time through the distribution of literature highlighting scientific support for the device. Furthermore, as the NeuroStar TMS becomes more common in clinical practice, support and enthusiasm will grow. As positive testimonials from patients and clinicians accumulate, the claims of critics will carry diminishing weight.
Neuronetics is positioned in what appears to be a sea of opportunity. Their device is the only one to have overcome the hurdles of FDA testing, meaning that at the current time no competitor can advertise an FDA-approved alternative. This represents an enormous opportunity for unbounded expansion. With proper marketing, the benefits of the NeuroStar TMS will be largely self-evident.
The NeuroStar TMS fills a significant gap by addressing the needs of patients who fell between two treatment categories: those whose prescribed pharmaceutical therapy was not working, yet whose symptoms were not severe enough to warrant more invasive procedures. The NeuroStar TMS represents an answer for patients who previously had no further options available. This device addresses a major unmet need in the market for treatment-resistant major depression.
The NeuroStar TMS has also received considerable attention in the press, including coverage from U.S. News and World Report, ABC, the Wall Street Journal, the Los Angeles Times, NBC Washington, Forbes, the Washington Post, and the New York Post (Neuronetics, 2009). This level of high-profile exposure helps establish the credibility of the device among both consumers and clinicians. Coverage of the device as a major medical breakthrough represents a key opportunity for building and solidifying a loyal client base.
Although the underlying theory has been established for many years, the NeuroStar TMS is the first device of its kind on the market. In addition to the opportunities this creates, being a pioneer also presents risks. There is a possibility that the market will not accept the device, and negative press is a genuine threat. If patients and clinicians do not see the expected results, the device could fail. However, if preliminary results continue to hold, the likelihood of this outcome remains minimal.
As with any new device in a nascent market, continued existence depends on the risk of competition eroding market share. Currently, only two devices pose immediate competition: one is an implantable device requiring invasive surgery, and the other has not yet received FDA approval (Zwillich, 2007). Neither poses a current threat, but if the non-invasive competitor gains approval, it could significantly challenge Neuronetics. At present, Neuronetics holds a monopoly, and any competitive entry could fundamentally alter the market dynamics for TMS devices.
As the popularity and success of the NeuroStar TMS grow, copycat devices will likely begin to appear. Entering the market requires a considerable amount of capital, and any new entrant would need to secure patents and obtain FDA approval before posing a real threat — devices without FDA clearance cannot be used in clinical settings, and clinicians cannot seek insurance reimbursement for their use. These two barriers present significant obstacles to competitive entry, but they are not insurmountable. It is likely that as the NeuroStar TMS grows in popularity, Neuronetics will eventually face meaningful competition. That is simply the price of success.
The NeuroStar TMS stands to become a widely adopted medical device for patients with treatment-resistant major depression who currently have no solution. The company has an innovative product representing a new treatment procedure grounded in solid evidence. It is first on the market and has already demonstrated success in one of the largest clinical trials in the nation.
"Staged growth plan from launch to global expansion"
Neuronetics represents an exciting opportunity for the entrepreneur with long-term vision. The worst mistake that the company could make would be to expand too rapidly. Rapid growth may occur, but with it comes an increased risk of errors that could damage the company's reputation and customer base. This scenario must be avoided in order to preserve the company's longevity.
You’re 57% through this paper. Sign up to read the remaining 1 section.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.